2 results match your criteria: "CHRU de Lille and University of Lille II[Affiliation]"
VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study.
ERJ Open Res
October 2015
Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles (ULB), Brussels, Belgium.
Salvage chemotherapy (CT) for relapsing or refractory small cell lung cancer (SCLC) remains disappointing. experiments showed that valproic acid increases apoptosis of SCLC cell lines exposed to doxorubicin, vindesine and bis(2-chloroethyl)amine. The primary objective of this phase II study was to determine whether epigenetic modulation with valproic acid in addition to a doxorubicin, vindesine and cyclophosphamide (VAC) regimen improves 6-month progression-free survival (PFS).
View Article and Find Full Text PDFValproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study.
Eur Respir J
January 2011
Dept of Pulmonary and Thoracic Oncology, CHRU de Lille and University of Lille II, Lille, France.
No treatment is recommended for patients with malignant mesothelioma (MM) failing after first-line cisplatin-based chemotherapy. In vitro data suggested that valproic acid, a histone deacetylase inhibitor (HDACi), had a proapoptotic effect and synergised with doxorubicin to induce apoptosis in MM cells. Our primary end-point was to determine response rate of combined valproic acid and doxorubicin in patients with unresectable MM failing after platinum-based chemotherapy.
View Article and Find Full Text PDF